This site is intended for UK healthcare professionals

 
This promotional video has been developed, organised, and funded by Novartis Pharmaceuticals. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this video has been provided by OmniaMed Communications.

Click here to access ENTRESTO® (sacubitril/valsartan) prescribing information.
ENTRESTO® (sacubitril/valsartan) is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction1
Adverse events reporting information can be found at the bottom of the page.
novartis-logo-transparent
05:40

Heart Failure Foundation Course: The role of primary care in the management of heart failure

1 August 2024

Sponsored

05:40
In this summary video, Dr Jim Moore (General Practitioner with a special interest (GPSI) in cardiovascular medicine, Gloucestershire) outlines the role of primary care in making an early diagnosis of heart failure, the importance of NT-proBNP testing and the ongoing monitoring of patients.

To watch the full on-demand video and other videos in this series click here (this will direct to Novartis promotional content).


Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email [email protected] or call 01276 698370. 

References

  1. ENTRESTO® (sacubitril/valsartan) Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/medicine/3124

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

BJC TV

To continue, please confirm that you are a UK healthcare professional.